Corcept Therapeutics develops treatments for severe disorders. They offer Korlym tablets for endogenous Cushings syndrome. Relacorilant is in Phase III trials for Cushings syndrome, adrenal cancer, cortisol excess, prostate cancer, and platinum-resistant ovarian tumors. Dazucorilant is in Phase II trial for amyotrophic lateral sclerosis. Miricorilant is in Phase IIb trial for nonalcoholic steatohepatitis. They also develop treatments for antipsychotic-induced weight gain.
| Indicator | Value |
|---|---|
| PER | 52.2 |
| EV/EBITDA | 52.4 |
| Price/Free Cash Flow' | 37.6 |
| ROIC | 28.9% |
| Net Debt/EBITDA | -0.9 |